From the blog

Evaluating Ivonescimab As a Potential Treatment for Pleural Mesothelioma Patients Whose Cancer Has Returned After Previous Immunotherapy and Chemotherapy (Bi-MAPS)

Primary Outcome Measures The analysis of the primary efficacy endpoint will be conducted in all eligible patients, based on the disease control rate (DCR) at 12 weeks according to mRECIST 1.1 for mesothelioma, which was defined as the proportion of patients with compete response (CR), partial response (PR) or stable[…]

Read More »

Wildfires Continue to Affect Los Angeles Area

The Los Angeles County Sheriff’s Department issued warnings to Altadena deputies about toxins like asbestos being in the air. Deputies are recommended to wear N95 masks to help prevent toxin inhalation. The Fire Department’s hazmat team in Altadena said the air is hazardous, containing lead, asbestos, and other harmful particulates.[…]

Read More »

Drug Factories to Treat Mesothelioma

Researchers from Rice University and Baylor College of Medicine developed a new treatment that can eliminate advanced stage mesothelioma tumors in mice within days. The breakthrough treatment used Rice’s cytokine drug factory implants with a checkpoint inhibitor drug. This combination is showing great potential in mesothelioma preclinical trials. The treatment[…]

Read More »

The Diagnostic Accuracy and Clinical Value of FAPI PET in Pleural Mesothelioma (FAPI-PM)

Primary Outcome Measures The diagnostic performance (sensitivity, specificity, positive predicative value, negative predicative value, and overall diagnostic accuracy – all parameters in %). in of FAPI PET compared to routine imaging modalities, including FDG PET/CT, in suspected PM lesions. Secondary Outcome Measures Calculate the proportion of patients where the location[…]

Read More »

Decision Making Tools for Mesothelioma

Mesothelioma, a cancer mainly caused by asbestos exposure, is very rare and aggressive. There are many challenges that doctors face when diagnosing, treating, and managing this cancer. Advances in medical technology and data analytics are helping doctors make crucial decisions for patients struggling with the hard to treat and deadly[…]

Read More »

MARS 2 Trial for Mesothelioma

Malignant pleural mesothelioma is a deadly cancer mainly caused by asbestos exposure. It is a hard-to-treat cancer due to its aggressiveness. The cancer affects the pleura, which is the membrane that covers the lungs. A trial known as MARS 2 tried to find out if extended pleurectomy and decortication could[…]

Read More »

The Diagnostic Accuracy and Clinical Value of FAPI PET in Pleural Mesothelioma (FAPI-PM)

Primary Outcome Measures Calculate the proportion of patients where the location of the intended pleural biopsy is altered due to FAPI PET/CT replacing FDG PET/CT. Secondary Outcome Measures Compare the cancer stage (IASCL 9th edition TNM-classification) as determined by FAPI PET/CT compared to conventional imaging (including FDG PET/CT) at primary[…]

Read More »

Changing Gut Bacteria Could Improve Effectiveness of Certain Treatments for Mesothelioma

A new cancer study has found that certain gut bacteria could influence a person’s immune system when fighting mesothelioma, an aggressive cancer of the linings of certain areas of the body including the lungs, abdomen, heart, and testicles. This has led experts to believe that in future cases of mesothelioma,[…]

Read More »

New Testing for Asbestos in Talc Based Products

In 2023, Congress passed a new law requiring that the U.S. Food and Drug Administration release new industry standards for asbestos testing in products. The agency will require all talc-containing products to be tested for asbestos. This new proposal follows years of lawsuits against Johnson & Johnson and other companies[…]

Read More »

Skip to content